Close Menu

Somalogic

SomaLogic Raises $10M

NEW YORK (GenomeWeb News) – SomaLogic has raised $10 million in equity financing, the company said in a document filed with the US Securities and Exchange Commission on Tuesday.

Agilent and SomaLogic said this week that they have entered an agreement to expand access to SomaLogic's SOMAscan protein biomarker discovery platform by placing it in select academic and contract research centers.

NEW YORK (GenomeWeb News) – Agilent and SomaLogic said today that they have entered an agreement to expand access to Somalogic's SOMAscan protein biomarker discovery platform by placing it in select academic and contract research centers.

On a conference call last month following the release of its Q1 earnings, Vermillion CEO Thomas McLain announced that the company would be taking over from Quest Diagnostics as leader of commercialization efforts for its OVA1 ovarian cancer diagnostic (

Researchers led by the Harvard Stem Cell Institute and Brigham and Women's Hospital have identified a protein — GDF11 — using Somalogic's Somascan technology, that they showed can reverse features of age-related heart disease in mice.

British diagnostic tools provider Avacta plans to introduce a new high-density protein microarray platform for use in drug and biomarker discovery by the end of next year, CEO Alastair Smith told BioArray News this week.

Under its new Parkinson's Disease Biomarker Program, the National Institute of Neurological Disorders and Stroke has funded nine research teams, most of which involve proteomic approaches, to attempt to identify biomarkers that could be used as either predictive or prognostic too

NEW YORK (GenomeWeb News) – SomaLogic, New England Biolabs, and Gilead Sciences are suing Enzymatics in federal court for patent infringement.

Proteomics diagnostics firm Somalogic reported data this week supporting the utility of its blood-based 13-protein panel for the detection of malignant mesothelioma.

Quest Diagnostics has begun offering a test for measuring free epidermal growth factor receptor using Somalogic's aptamer-based Somamer technology.

Pages

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.